Evidence map›Paper›PMID 28424889›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

E A Korkeila, T Salminen, R Kallio, M Mikkola, P Auvinen, S Pyrhönen, R Ristamäki

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00669370 (Biweekly Docetaxel), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00669370 phase2unknown statusnot on this map

Biweekly Docetaxel (Taxotere®)in Combination With Capecitabine (Xeloda®)as First-Line Treatment in Patients With Advanced Gastric Cancer

TypeinterventionalSponsorUniversity of TurkuRan2006Enrolled50ConditionsStomach NeoplasmsArmsdocetaxel and capecitabine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

E A KorkeilaDepartment of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland. eija.korkeila@tyks.fi.
T SalminenDepartment of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland.
R KallioDepartment of Oncology and Haematology, Oulu University and Oulu University Hospital, Oulu, Finland.
M MikkolaDepartment of Oncology, Vaasa Central Hospital, Vaasa, Finland.
P AuvinenFaculty of Medicine and Cancer Center and Department of Oncology, University of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.
S PyrhönenDepartment of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland.
R RistamäkiDepartment of Oncology, University of Turku and Turku University Hospital, Hämeentie 11, PB 52, FI-20521, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer.

methodsFifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-randomized, multicentre phase II trial to receive intravenous docetaxel 50 mg/m

resultsForty-six patients were evaluable for QOL analyses. No deterioration in global health status was found. Social functioning scores improved, and eating difficulties and pain were alleviated during treatment. The most common grade 3 or 4 toxicity was neutropenia (47%), whereas neutropenic fever was uncommon (6%). The clinical benefit rate was 60%, including complete and partial responses as well as stabilized disease. Median overall survival was 8.8 months (95% CI 5.8-11.9 months), and median time to progression was 6.2 months (95% CI 4.9-7.5 months).

conclusionsBiweekly docetaxel with capecitabine is a feasible treatment in AGC, delivered on an outpatient basis, with no need for central venous access device. No deterioration of global health status was reported. In addition, pain and eating difficulties were alleviated during study treatment. This trial is registered at ClinicalTrials.gov , number NCT00669370.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDisease ProgressionDocetaxelEsophageal NeoplasmsFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeStomach NeoplasmsTaxoidsCapecitabineDocetaxelTaxoidsAdvanced gastro-oesophageal cancerChemotherapyPalliative treatmentQuality of life

Identifiers

PMID28424889
PMCPMC5527066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.